Flow cytometry analysis of tumor, non-tumor, and blood from this cohort at day 18 post injection tumors, 14 days of Ibudilast treatment, identified an increase in CD8 T cells specific to the tumor, while other immune cell populations were unchanged (Figure 5G, Supplemental Figures 2, 3). This evidence concerns the gene CD8A and neoplasm.